


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.(Previously presented) A compound according to Formula I herein below:



**Formula (I)**


wherein:

$Z_1$  is independently selected from the group consisting of hydrogen and  $C_{1-6}$  alkyl;


$R^1$  is independently selected from the group consisting of hydrogen, halogen,  $C_{1-4}$  alkyl,  $-C(O)(C_{1-6}$  alkyl),  $-CO_2(C_{1-6}$  alkyl),  $-C(O)(aryl)$  and  $-C(O)(C_{1-6}$  alkylaryl);

$G^1$  is independently selected from the group consisting of  $CH_2-CH_2$  and  $CH=CH$ ;

$G^2$  is independently selected from  $C_{4-7}$  alkyl or a group of the formula (a), (b) or (c):




(a)



(b)

or




(c)

;


$R^2$  is independently selected from formula (d), (e) or (f):



(d)



(e)



(f)

wherein

$X$  is independently selected from the group consisting of a bond,  $NR^3$  and  $C_{1-4}$  alkyl;

$R^3$  is independently selected from the group consisting of hydrogen, optionally substituted  $C_{1-6}$  alkyl and  $C_{1-4}$  alkyl-aryl;

$Z$  is independently selected from the group consisting of optionally substituted  $C_{1-6}$  alkyl, and  $C_{1-6}$  alkyl- $Y^2$ ; or  $Z$  and  $R^3$  together may form a 4-7 membered ring, or  $Z$  and  $Ar$  together may form a 4-7 membered ring;

$Ar$  is independently selected from the group consisting of an optionally substituted phenyl ring, an optionally substituted 5- or 6- membered aromatic heterocyclic ring, an

optionally substituted bicyclic aromatic or heteroaromatic ring system, and an optionally substituted tricyclic ring system;

Ar<sup>1</sup> and Ar<sup>2</sup> are independently selected from an optionally substituted phenyl ring, or an optionally substituted 5- or 6- membered aromatic heterocyclic ring;

Y is independently selected from a group consisting of a bond, -NHCO-, -CONH-, -CH<sub>2</sub>-, and -(CH<sub>2</sub>)<sub>m</sub>Y<sup>1</sup>(CH<sub>2</sub>)<sub>n</sub>-;

Y<sup>1</sup> is O, S, SO<sub>2</sub>, or CO ;

m and n each represent zero or 1 such that the sum of m+n is zero or 1; provided that when R<sup>2</sup> represents a group of formula (d) and X is a bond, any substituent present in Ar *ortho* to the carboxamide moiety is a hydrogen or a methoxy group ;

Y<sup>2</sup> is independently selected from a group consisting of NR<sup>3</sup>, O, S, -NHC(O)-, and -C(O)NH-;

t is independently 0 or an integer between 1 and 3.

2.(Previously presented) A compound according to claim 1 which is:

2-Methyl-quinoline-5-carboxylic acid (trans-4- {2-[6-(2-methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;

8-Chloro-2-methyl-quinoline-5-carboxylic acid (trans-4- {2-[6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide ;

8-Methyl-quinoline-5-carboxylic acid (4- {2-[6-butyryl-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide ;

2-Methyl-quinoline-5-carboxylic acid (trans-4- {2-[6-butyryl-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide ;

2-Methyl-quinoline-5-carboxylic acid (trans-4- {2-[6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;

N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-1-(2-phenylethyl)-1-(phenylmethyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2-hydroxy-2,2-diphenylethyl)urea;

N-[2-( {[(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)amino]carbonyl}amino)ethyl]-4-methylbenzenesulfonamide;

1,1-dimethylethyl N-{{[trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)amino]carbonyl}-L-phenylalaninate;  
N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-(3,3-diphenylpropyl)-N-methylurea;  
3-[{[trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)amino]carbonyl}amino)methyl]benzenesulfonamide formate;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2-hydroxy-1,1-diphenylethyl)urea formate;  
N,N'-bis(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)urea  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(3-hydroxy-3,3-diphenylpropyl)urea formate;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[(1S)-2-hydroxy-1-methyl-2,2-diphenylethyl]urea formate;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(cyclohexylmethyl)urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[(2-hydroxyphenyl)methyl]urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[(4-fluorophenyl)methyl]urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[(4-fluorophenyl)methyl]urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2,3-dihydro-1H-inden-1-yl)urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(3-phenylpropyl)urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[(4-chlorophenyl)methyl]urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1,1a,6,6a-tetrahydrocyclopropa[a]inden-1-yl)urea;  
N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-(3-hydroxypropyl)-N-(phenylmethyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-{[4-(trifluoromethyl)phenyl]methyl}urea;  
1,1-dimethylethyl 2-{{[trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl]amino]carbonyl}benzoate;  
N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2,2-diphenylpropanamide;  
N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4-[(phenylcarbonyl)amino]benzamide;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2,2-diphenylethyl)urea;  
N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N,1-bis(phenylmethyl)urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(3,3-diphenylpropyl)urea;  
1-Benzyl-3-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-urea ;  
or  
1-(1-Naphthalen-1-yl-ethyl)-3-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-urea.

3.(Previously presented) A compound according to claim 1 which is:  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2-(4-pyridinyl)acetamide;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2-pyridinylmethyl)urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(4-hydroxycyclohexyl)urea;  
N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-methyl-N-(phenylmethyl)urea;  
1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[2-(2-pyridinyl)ethyl]urea;  
N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2-(2-pyrimidinylthio)acetamide;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-quinolinecarboxamide;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-1-methyl-1H-indole-2-carboxamide;

(2E)-N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4-oxo-4-phenyl-2-butenamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1H-indol-3-ylmethyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1H-benzimidazol-2-ylmethyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1,2,3,4-tetrahydro-2-naphthalenyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1,2,3,4-tetrahydro-1-naphthalenyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N,N-dimethylphenylalaninamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(4-phenylbutyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2-methyl-1,2,3,4-tetrahydro-2-naphthalenyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2-methyl-1,2,3,4-tetrahydro-2-naphthalenyl)urea;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4-(2-pyridinyl)-1-piperazinecarboxamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[2-(4-pyridinyl)ethyl]urea formate;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2,2-diphenylacetamide;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2,2-diphenylacetamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[3-(1H-imidazol-1-yl)propyl]urea formate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-{[4-(trifluoromethyl)phenyl]methyl}urea;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4-(phenylmethyl)-1-piperazinecarboxamide;

N-{5-[(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)amino]-5-oxopentyl}benzamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1H-indol-3-ylmethyl)urea formate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-{[3-(dimethylamino)phenyl]methyl}urea formate;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(4-methylphenyl)-3-phenylpropanamide;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4,4-diphenylbutanamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2-(methoxy)-2,2-diphenylacetamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1-naphthalenylmethyl)urea formate;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4-(phenylmethyl)-1-piperazinecarboxamide formate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2-{3-[hydroxy(3-pyridinyl)methyl]phenyl}ethyl)urea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[1-(phenylmethyl)-4-piperidinyl]urea formate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(3-phenylpropyl)urea trifluoroacetate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[5,8-bis(methoxy)-1,2,3,4-tetrahydro-2-naphthalenyl]urea formate;

N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-(3,3-diphenylpropyl)-N-propylurea;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(3,3-diphenylpropyl)urea formate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1-methyl-2,2-diphenylethyl)urea formate;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2-[(2-methylphenyl)(phenyl)methyl]benzamide;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4-(diethylamino)-2,2-diphenylbutanamide;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(2-{3-[hydroxy(3-pyridinyl)methyl]phenyl}ethyl)urea formate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-(1,1-dimethyl-3,3-diphenylpropyl)urea formate;

N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-(3,3-diphenylpropyl)-N-ethylurea formate;

N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-methyl-N-(2,2,2-triphenylethyl)urea;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-phenyl-3-{3-[(phenylmethyl)oxy]phenyl}propanamide;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2-hydroxy-2,2-diphenylacetamide trifluoroacetate;

N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-ethyl-N-(3-hydroxy-3,3-diphenylpropyl)urea formate;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2-{bis[4-(dimethylamino)phenyl]methyl}benzamide;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[4-(dimethylamino)phenyl]-3-phenylpropanamide trifluoroacetate;

N'-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-N-(3,3-diphenylpropyl)-N-(phenylmethyl)urea formate;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-2,2-bis(4-chlorophenyl)acetamide trifluoroacetate;

N-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-4-(diethylamino)-2,2-diphenylbutanamide trifluoroacetate;

1-(trans-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl)-3-[3-(4-biphenylyl)-3-(4-chlorophenyl)-3-hydroxypropyl]urea formate;

1-(4-Bromo-benzyl)-3-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-urea;

1-(1,1-Diphenyl-methyl)-3-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-urea;

1-(2-Methoxy-benzyl)-3-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-urea;

1-(3-Methoxy-benzyl)-3-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-urea;

1-(4-Methoxy-benzyl)-3-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-urea;

2-Methyl-quinoline-5-carboxylic acid {4-[2-(1,4-dihydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

8-Chloro-2-methyl-quinoline-5-carboxylic acid {4-[2-(1,4-dihydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

8-Methoxy-2-methyl-quinoline-5-carboxylic acid {4-[2-(1,4-dihydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

Quinoxaline-5-carboxylic acid {4-[2-(1,4-dihydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

Quinoline-5-carboxylic acid {*trans*-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide;

8-Methyl-quinoline-5-carboxylic acid {*trans*-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide;

2-Methyl-quinoline-5-carboxylic acid {*trans*-4-[(1S,4S)-1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl) methyl]-cyclohexylmethyl}-amide;

8-Chloro-2-methyl-quinoline-5-carboxylic acid {*trans*-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide;

2,8-Dimethyl-quinoline-5-carboxylic acid {*trans*-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide;

1-((S)-1-Naphthalen-1-yl-ethyl)-3-{*trans*-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-urea;

1-((R)-1-Naphthalen-1-yl-ethyl)-3-{*trans*-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-urea;

Isoquinoline-1-carboxylic acid {*trans*-4-[(1*S*,4*R*)-2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

Acridine-9-carboxylic acid {*trans*-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

2,3-Dihydro-naphthalene-1-carboxylic acid {*trans*-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

6,7-Dihydro-quinoline-8-carboxylic acid {*trans*-4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide;

9-[2-(*trans*-4-{{1-(2-Methyl-quinolin-5-yl)-methanoyl}-amino}-cyclohexyl)-ethyl]-1,4-dihydro-1,4-epiazano-naphthalene-6-carboxylic acid methyl ester;

9-(2-{{*trans*-4-[3-((S)-1-Naphthalen-1-yl-ethyl)-ureido]-cyclohexyl}-ethyl}-1,4-dihydro-1,4-epiazano-naphthalene-6-carboxylic acid methyl ester;

9-[2-(*trans*-4-{{1-(2-Methyl-quinolin-5-yl)-methanoyl}-amino}-cyclohexyl)-ethyl]-1,2,3,4-tetrahydro-1,4-epiazano-naphthalene-6-carboxylic acid methyl ester;

(1*S*,4*R*)-9-(2-{{4-[(1-Quinolin-5-yl-methanoyl)-amino]-cyclohexyl}-ethyl}-1,2,3,4-tetrahydro-1,4-epiazano-naphthalene-6-carboxylic acid methyl ester;

9-(2-{{*trans*-4-[3-((S)-1-Naphthalen-1-yl-ethyl)-ureido]-cyclohexyl}-ethyl}-1,2,3,4-tetrahydro-1,4-epiazano-naphthalene-6-carboxylic acid methyl ester;

1-(*trans*-4-{{2-[6-(2-Methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl}-3-((S)-1-naphthalen-1-yl-ethyl)-urea;

Quinoline-5-carboxylic acid (*trans*-4-{{2-[6-(2-methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl}-amide;

8-Chloro-quinoline-5-carboxylic acid (*trans*-4-{{2-[6-(2-methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl}-amide;

8-Chloro-2-methyl-quinoline-5-carboxylic acid (*trans*-4-{{2-[6-(2-methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl}-amide;

8-Methyl-quinoline-5-carboxylic acid (4-{{2-[(1*S*,4*R*)-6-(2-methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl}-amide;

2,8-Dimethyl-quinoline-5-carboxylic acid (*trans*-4-{{2-[6-(2-methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl}-amide;

1-(*trans*-4-{{2-[6-(2-Methyl-propanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl}-3-((R)-1-naphthalen-1-yl-ethyl)-urea;

1-(trans-4-{2-[6-Butyryl-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-3-((S)-1-naphthalen-1-yl-ethyl)-urea;  
Quinoline-5-carboxylic acid (trans-4-{2-[6-butyryl-propanoyl]-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;  
8-Chloro-2-methyl-quinoline-5-carboxylic acid (trans-4-{2-[6-butyryl-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;  
Quinoline-5-carboxylic acid (trans-4-{2-[6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;  
1-((S)-1-Naphthalen-1-yl-ethyl)-3-(trans-4-{2-[6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-urea;  
8-Methyl-quinoline-5-carboxylic acid (trans-4-{2-[6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;  
2,8-Dimethyl-quinoline-5-carboxylic acid (trans-4-{2-[6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;  
8-Methoxy-2-methyl-quinoline-5-carboxylic acid (trans-4-{2-[6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-amide;  
1-((R)-1-Naphthalen-1-yl-ethyl)-3-(4-{2-[(1S,4R)-6-(2-phenyl-ethanoyl)-1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl]-ethyl}-cyclohexyl)-urea;  
Quinoline-5-carboxylic acid methyl- {trans-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide  
8-Methyl-quinoline-5-carboxylic acid methyl- {trans-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide;  
2,8-Dimethyl-quinoline-5-carboxylic acid methyl- {trans-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide;  
8-Chloro-quinoline-5-carboxylic acid methyl- {4-[(1S,4S)-1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide; or  
8-Chloro-2-methyl-quinoline-5-carboxylic acid methyl- {trans-4-[1-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)methyl]-cyclohexylmethyl}-amide.

4.(Currently amended) A pharmaceutical composition for the treatment of ~~muscarinic acetylcholine receptor mediated~~ diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.

5.(Cancelled )

6.(Currently amended) A method of treating a muscarinic acetylcholine receptor mediated disease selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis in a [[mammal]] human in need thereof comprising administering to said [[mammal]] human an effective amount of a compound according to claim 1.

7.(Cancelled)

8.(Previously presented) A method according to claim 6 wherein administration is via inhalation via the mouth or nose.


9.(Original) A method according to claim 8 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.

10.(Previously presented) A method according to claim 9 wherein the compound is administered to a human.

11 and 12.(Cancelled )

13. (Previously presented) The compound according to Claim 1 wherein G1 is CH=CH.

14. (Previously presented) The compound according to Claim 1 wherein G2 is a

compound of formula (a) 

15. (Previously presented) The compound according to Claim 1 wherein R2 is X- Ar.

16. (Previously presented) The compound according to Claim 15 wherein X is bond.

17. (Previously presented) The compound according to Claim 16 wherein Ar is an optionally substituted bicyclic aromatic or heteroaromatic ring.

18. (Previously presented) The compound according to Claim 17 wherein Ar is a bicyclic heteroaromatic ring selected from indazolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, quinoxolinyl, quinazolinyl, cinnolinyl, isoquinolinyl, pyrazolo[1,5-a]pyrimidyl, pyrrolo[3,2-b]pyridyl, pyrrolo[3,2-c]pyridyl, thieno[3,2-b]thiophenyl, 1,2-dihydro-2-oxo-quinolinyl, 3,4-dihydro-3-oxo-2H-benzoxazinyl, or 1,2-dihydro-2-oxo-3H-indolyl.

19. (Previously presented) The compound according to Claim 18 wherein Ar is a quinoxaline ring.

20. (Previously presented) The compound which is Quinoxaline-5-carboxylic acid {4-[2-(1,4-dihydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-amide.

21. (new) The compound according to Claim 1 wherein Ar, Ar<sup>1</sup> and Ar<sup>2</sup> are independently substituted by one or more substituents selected from the group consisting of halogen, hydroxy, oxo, cyano, nitro, trifluoromethyl, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylenedioxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylsulfinyl, C<sub>1-4</sub>alkylthio, R<sup>7</sup>SO<sub>2</sub>N(R<sup>8</sup>)-, R<sup>7</sup>R<sup>8</sup>NSO<sub>2</sub>-, R<sup>7</sup>R<sup>8</sup>N-, R<sup>7</sup>R<sup>8</sup>NCO-, R<sup>7</sup>OC(O)- or R<sup>7</sup>CON(R<sup>8</sup>)-; and wherein each of R<sup>7</sup> and R<sup>8</sup> are independently a hydrogen, or C<sub>1-4</sub> alkyl group, or R<sup>7</sup>R<sup>8</sup> together form a C<sub>3-6</sub> alkylene chain.

22. (new) The compound according to Claim 1 wherein Ar and Ar<sup>2</sup> are optionally substituted by one or more 5- or 6-membered heterocyclic rings, and wherein the hetyerocyclic ring is optionally substituted by C<sub>1-2</sub> alkyl or R<sup>7</sup>R<sup>8</sup>N-; and wherein each of R<sup>7</sup> and R<sup>8</sup> are independently a hydrogen, or C<sub>1-4</sub> alkyl group, or R<sup>7</sup>R<sup>8</sup> together with the nitrogen to which they are attached form a C<sub>3-6</sub> alkylene chain.

23. (new) The compound according to Claim 1 wherein X is NR<sup>3</sup>.

24. (new) The compound according to Claim 1 wherein X is C<sub>1-4</sub> alkyl.

25. (new) The compound according to Claim 23 wherein R<sup>2</sup> is X-Ar.
26. (new) The compound according to Claim 24 wherein R<sup>2</sup> is X-Ar.
27. (new) A method of treating chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis in a human in need thereof, comprising administering to said human by inhalation via the mouth or nose, an effective amount of a composition according to claim 6.
28. (new) The composition according to Claim 6 in a form suitable for administration by oral or nasal inhalation.
29. (new) The composition according to Claim 28 characterized in that the form is suitable for administration by inhalation is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler, or a pressurized metered dose inhaler.
30. (new) The composition according to Claim 28, characterized in the form of an aerosol formulation.
31. (new) The composition according to Claim 29 wherein the pharmaceutical carrier is lactose or starch.